EP1200566A2 - Variante de glucoamylase - Google Patents

Variante de glucoamylase

Info

Publication number
EP1200566A2
EP1200566A2 EP00943688A EP00943688A EP1200566A2 EP 1200566 A2 EP1200566 A2 EP 1200566A2 EP 00943688 A EP00943688 A EP 00943688A EP 00943688 A EP00943688 A EP 00943688A EP 1200566 A2 EP1200566 A2 EP 1200566A2
Authority
EP
European Patent Office
Prior art keywords
glucoamylase
variant
amino acid
parent
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00943688A
Other languages
German (de)
English (en)
Inventor
Bjarne Ronfeldt Nielsen
Allan Svendsen
Henrik Pedersen
Jesper Vind
Hanne Vang Hendriksen
Torben Peter Frandsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Priority to EP08159171A priority Critical patent/EP2009098A1/fr
Publication of EP1200566A2 publication Critical patent/EP1200566A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/20—Preparation of compounds containing saccharide radicals produced by the action of an exo-1,4 alpha-glucosidase, e.g. dextrose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • the present invention relates to novel glucoamylase variants (mutants) of parent AMG with altered properties, in particular with improved thermal stability and/or increased specific activity, which variants are, e.g., suitable for starch conversion, m particular for producing glucose from starch, and for ethanol production, sweetener production. More specifically, the present invention relates to glucoamylase variants and the use of such variant enzymes.
  • Glucoamylase (1, 4-alpha-D-glucan glucohydrolase, EC 3.2.1.3) is an enzyme, which catalyzes the release of D-glucose from the non-reducing ends of starch or related oligo- and polysaccharide molecules.
  • Glucoamylases are produced by several filamentous fungi or yeasts, with those from Aspergillus being commercially most important.
  • the glucoamylase enzyme is used to convert cornstarch, which is already partially hydrolyzed by an alpha- amylase to glucose. The glucose is further converted by glucose isomerase to a mixture composed almost equally of glucose and fructose.
  • This mixture, or the mixture further enriched with fructose, is the commonly used high fructose corn syrup commercialized throughout the world.
  • This syrup is the world's largest tonnage product produced by an enzymatic process.
  • the three enzymes involved m the conversion of starch to fructose are among the most important industrial enzymes produced.
  • Glucoamylase is not as thermally stable as alpha- amylase or glucose isomerase and it is most active and stable at lower pH's than either alpha-amylase or glucose isomerase. Accordingly, it must be used in a separate vessel at a lower temperature and pH.
  • Glucoamylase from Aspergillus niger has a catalytic (aa 1-
  • Glucoamylase WWW page (Last changed 97/10/08) by Pedro M. Coutinho discloses informations concerning glucoamylases, including glucoamylases derivable from Aspergillus strains. Chemical and site-directed modifications in the Aspergillus s niger glucoamylase are listed.
  • the object of the present invention is to provide glucoamylase variants suitable for used in, e . g. , the 0 saccharification step in starch conversion processes.
  • thermostable glucoamylase variant means in the context of the present invention a glucoamylase variant, which has a higher T 1/2 (half-time) in comparison to a corresponding parent glucoamylase.
  • T 1/2 half-time
  • a glucoamylase variant with increased specific activity means in the context of the present invention a glucoamylase variant with increased specific activity towards o the alpha-1,4 linkages in the saccharide in question.
  • the specific activity is determined as k cat or AGU/mg (measured as described below in the "Materials & Methods" section) .
  • An increased specific activity means that the k caC or AGU/mg values are higher when compared to the k cat or AGU/mg values, 5 respectively, of the corresponding parent glucoamylase.
  • the inventors of the present invention have provided a number of variants of a parent glucoamylase with improved thermal stability and/or increased specific activity.
  • the improved thermal stability is obtained by mutating, e.g., by substituting and/or deleting, inserting selected positions in a parent glucoamylase. This will be described in details below.
  • Ala30* or A30* and insertion of an additional amino acid residue, such as lysine, is shown as:
  • a deletion of a consecutive stretch of amino acid residues, such as amino acid residues 30-33, is indicated as (30-33)* or
  • any amino acid residue may be substituted for the amino acid residue present in the position.
  • the alanine may be deleted or substituted for any other amino acid, i.e., any one of: R,N,D,A,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.
  • FIG. 1 shows the plasmid pCAMG91 containing the Aspergillus niger Gl glucoamylase gene.
  • a goal of the work underlying the present invention was to improve the thermal stability and/or increase the specific activity of particular glucoamylases, which are obtainable from fungal organisms, in particular strain of the Aspergillus genus and which themselves had been selected on the basis of their suitable properties in, e.g., starch conversion or alcohol fermentation.
  • the present inventors have surprisingly found that it is in fact possible to improve the thermal stability and/or increased specific activity of parent glucoamylases by modification of one or more amino acid resi- dues of the amino acid sequence of the parent glucoamylase.
  • the present invention is based on this finding.
  • the present invention relates to a variant of a parent glucoamylase comprising one or more mutations in the positions described further below.
  • Parent Glucoamylase contemplated according to the present invention include wild-type glucoamylases, fungal glucoamylases, in particular fungal glucoamylases obtainable from an Aspergillus strain, such as an Aspergillus niger or Aspergillus awamori glucoamylases and variants or mutants thereof, homologous glucoamylases, and further glucoamylases being structurally and/or functionally similar to SEQ ID NO:2.
  • Aspergillus niger glucoamylases Gl and G2 disclosed in Boel et al .
  • Glucoamylases Gl and G2 from Aspergillus niger are synthesized from two different but closely related mRNAs" , EMBO J. 3 (5), p. 1097-1102.
  • the G2 glucoamylase is disclosed in SEQ ID NO: 2.
  • the AMG backbone is derived from Talaromyces, in particular T. emersonii disclosed in WO 99/28448 (See SEQ ID NO: 7 of WO 99/28448) .
  • Contemplated commercially available parent glucoamylases include AMG from Novo Nordisk, and also glucoamylase from the companies Genencor, Inc. USA, and Gist-Brocades, Delft, The Netherlands .
  • the invention relates to a variant of a parent glucoamylase, comprising an alteration at one or more of the following positions: 59, 66, 72, 119, 189, 223, 227, 313, 340, 342, 352, 379, 386, 393, 395, 402, 408, 416, 425, 427, 444, 486, 490, 494, wherein (a) the alteration is independently (i) an insertion of an amino acid downstream of the amino acid which occupies the position,
  • each position corresponds to a position of the amino acid sequence of the parent glucoamylase having the amino acid sequence of SEQ ID NO: 2.
  • the invention relates to a variant of a parent glucoamylase which parent glucoamylase has an amino acid sequence which has a degree of identity to the amino acid sequence of SEQ ID NO: 2 of at least about 65%, preferably at least about 70%, more preferably at least about 80%, even more preferably at least about 90%, most preferably at least about 95%, and even most preferably at least about 97%.
  • the invention also relates to a variant of a parent glucoamylase, comprising one or more of the following: V59A, L66V/R, T72I, S119P, I189T, Y223F, F227Y, N313G, S340G, E342A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V, preferably E342T, K352R, S356G, T379A, S386K,N,R,P, A393R, S395R, Y402F, E408R, T416A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,E,W,Y,V preferably T416H, A425T, N427S/M, S444G, S486G, T490A, T494P/A, wherein (a) the variant
  • mutations include: L66R+Y402F+N427S+S486G+A1V; N427M+S44G+V470M+T2K+S30P; T416H+Y402F+312Q+S119P; A425T+E408R+E386K+A495T; T379A+T2E+S386K+A393R; S386N+E408R; L66V+T2R+S394P+Y402F+RL; S386R+T2R+A393R; I189T+Y223F+F227Y+S119P+Y402F;
  • V59A+N313G+L66R V59A+N313G+S340G; V59A+N313G+S395R V59A+N313G+L66R+S340G;V59A+N313G+S340G+S395R;
  • V59A+Y402F+S340G V59A+Y402F+S395R; V59A+Y402F+L66R+S395R
  • V59A+E408R+S395R V59A+E408R+S340G; V59A+E408R+S395R+S340G;
  • N313G+A393R V59A+N313G+A393R+Y402F; V59A+S340G; L66R+S340G;
  • N313G+L66R N313G+L66R+S340G; A393R+S340G; A393R+L66R+S340G;
  • the invention also relates to a variant of a parent glucoamylase which parent glucoamylase is encoded by a nucleic acid sequence which hybridizes under medium, more preferably high stringency conditions, with the nucleic acid sequence of
  • SEQ ID NO: 1 or its complementary strand.
  • the invention relates to a variant of a parent glucoamylase with improved thermal stability, in particular in the range from 40-80°C, preferably 63-75°C, in particular at pH 4-5, using maltodextrin as the substrate, said variant comprising one or more mutations in the following positions in the amino acid sequence shown in SEQ ID NO: 2: 59, 66, 72, 119, 189, 223, 227, 313, 340, 342, 352, 379, 386, 393, 395, 402, 408, 416, 425, 427, 444, 486, 490, 494, or in a corresponding position in a homologous glucoamylase which displays at least 60% homology with the amino acid sequences shown in SEQ ID NO: 2.
  • E342A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V preferably E342T, K352R, S356G, T379A, S386K,N,R,P, A393R, S395R, Y402F, E408R, T416A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,E,W,Y,V, preferably T416H, A425T, N427S/M, S444G, S486G, T490A, T494P/A.
  • mutations include: E408R+A425T+S465P+T494A, A425T+E408R+S386K+A495T, T379A+T2E+S386K+A393R, S386N+E408R,
  • Glucoamylase variants of the invention are contemplated to have improved termostability .
  • Examples 2 and 4 show this for selected variants of the invention.
  • the invention relates to a variant of a parent glucoamylase with improved specific activity, said variant comprising one or more mutations in the following positions in the amino acid sequence shown in SEQ ID NO: 2: 59, 66, 72, 119, 189, 223, 227, 313, 340, 342, 352, 379, 386, 393, 395, 402, 408, 416, 425, 427, 444, 486, 490, 494, preferably 189, 223, 227 or in a corresponding position in a homologous glucoamylase which displays at least 60% homology with the amino acid sequences shown in SEQ ID NO: 2.
  • T416A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,E,W,Y,V preferably T416H, A425T, N427S/M, S444G S486G, T490A, T494P/A, preferably I189T, Y223F, F227Y.
  • mutations include: I189T+Y223F+F227Y+S119P+Y402F;
  • Glucoamylase variants of the invention are contemplated to have increased specific activity.
  • Example 3 shows this for a selected variant of the invention.
  • the homology referred to above of the parent glucoamylase is determined as the degree of identity between two protein sequences indicating a derivation of the first sequence from the second.
  • the homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, p. 443-453) .
  • the mature part of a polypeptide encoded by an analogous DNA sequence of the invention exhibits a degree of identity preferably of at least 80%, at least 90%, more preferably at least 95%, more preferably at least 97%, and most preferably at least 99% with the mature part of the amino acid sequence shown in SEQ ID NO: 2.
  • parent glucoamylase is the Aspergillus niger Gl glucoamylase (Boel et al . (1984), EMBO J.
  • the parent glucoamylase may be a truncated glucoamylase, e.g., the A . niger G2 glucoamylase (SEQ ID NO: 2) .
  • the parent glucoamylase comprises the amino acid sequences of SEQ ID NO: 2; or allelic variants thereof; or a fragment thereof that has glucoamylase activity.
  • a fragment of SEQ ID NO: 2 is a polypeptide which has one or more amino acids deleted from the amino and/or carboxyl terminus of this amino acid sequence.
  • the AMG G2 (SEQ ID NO: 2) is a fragment of the Aspergillus niger Gl glucoamylase (Boel et al . (1984), EMBO J. 3 (5), p. 1097-1102) having glucoamylase activity.
  • An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations.
  • Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences.
  • An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.
  • the amino acid sequences of homologous parent glucoamylases may differ from the amino acid sequence of SEQ ID NO: 2 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues.
  • amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20- 25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
  • the isolated parent glucoamylase is encoded by a nucleic acid sequence which hybridises under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with a nucleic acid probe which hybridises under the same conditions with (i) the nucleic acid sequence of SEQ ID NO: 1, (ii) the cDNA sequence of SEQ ID NO:l, (iii) a sub-sequence of (i) or (ii) , or (iv) a complementary strand of (i) , (ii) , or (iii) (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, Molecular Cloning, A Laboratory Manual , 2d edition, Cold Spring Harbor, New York) .
  • the sub-sequence of SEQ ID NO: 1 may be at least 100 nucleotides or preferably at least 200 nucleotides. Moreover, the sub-sequence may encode a polypeptide fragment, which has glucoamylase activity.
  • the parent polypeptides may also be allelic variants or fragments of the polypeptides that have glucoamylase activity.
  • the nucleic acid sequence of SEQ ID NO: 1 or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO: 2, or a fragment thereof, may be used to design a nucleic acid probe to identify and clone DNA encoding polypeptides having glucoamylase activity, from strains of different genera or species according to methods well known in the art.
  • probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein.
  • Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 35 nucleotides in length.
  • Probes Longer probes can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with 2 P, 3 H, 35 S, biotm, or avidm) . Such probes are encompassed by the present invention.
  • genomic DNA or cDNA library prepared from such other organisms may be screened for DNA, which hybridizes with the probes described above and which encodes a polypeptide having glucoamylase.
  • Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques.
  • DNA from the libraries or the separated DNA may be transferred to and immobilised on nitrocellulose or other suitable carrier material .
  • the carrier material is used in a Southern blot .
  • hybridisation indicates that the nucleic acid sequence hybridises to a nucleic acid probe corresponding to the nucleic acid sequence shown m SEQ ID NO: 1 its complementary strand, or a sub-sequence thereof, under very low to very high stringency conditions. Molecules to which the nucleic acid probe hybridises under these conditions are detected using X-ray film.
  • the carrier material is finally washed three times each for 15 minutes using 2 x SSC, 0.2% SDS preferably at least at 45°C
  • very low stringency more preferably at least at 50 °C (low stringency) , more preferably at least at 55°C (medium stringency) , more preferably at least at 60°C (medium-high stringency) , even more preferably at least at 65°C (high stringency) , and most preferably at least at 70°C (very high stringency) .
  • stringency conditions are defined as prehyb ⁇ dization, hybridisation, and washing post- hybridisation at 5°C to 10°C below the calculated T m using the calculation according to Bolton and McCarthy (1962, Proceedings of the National Academy of Sciences USA 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6 , 6 mM EDTA, 0.5% NP-40, IX Denhardt ' s solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.
  • the carrier material is washed once in 6X SCC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T m .
  • the present invention also relates to isolated nucleic acid sequences produced by (a) hybridising a DNA under very low, low, medium, medium-high, high, or very high stringency conditions with the sequence of SEQ ID NO:l, or its complementary strand, or a sub-sequence thereof; and (b) isolating the nucleic acid sequence.
  • the sub-sequence is preferably a sequence of at least 100 nucleotides such as a sequence, which encodes a polypeptide fragment, which has glucoamylase activity.
  • Contemplated parent glucoamylases have at least 20%, preferably at least 40%, more preferably at least 60%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 100% of the glucoamylase activity of the mature glucoamylase of SEQ ID NO: 2.
  • the DNA sequence encoding a parent glucoamylase may be isolated from any cell or microorganism producing the glucoamylase in question, using various methods well known in the art.
  • a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the glucoamylase to be studied.
  • labeled oligonucleotide probes may be synthesized and used to identify glucoamylase-encoding clones from a genomic library prepared from the organism in question.
  • a labelled oligonucleotide probe containing sequences homologous to another known glucoamylase gene could be used as a probe to identify glucoamylase-encoding clones, using hybridization and washing conditions of very low to very high stringency. This is described above .
  • Yet another method for identifying glucoamylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming glucoamylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for glucoamylase (i.e., maltose), thereby allowing clones expressing the glucoamylase to be identified.
  • an expression vector such as a plasmid, transforming glucoamylase-negative bacteria with the resulting genomic DNA library
  • the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e . g. the phosphoroamidite method described S.L. Beaucage and M.H. Caruthers, (1981), Tetrahedron Letters 22, p. 1859-1869, or the method described by Matthes et al . , (1984), EMBO J. 3, p. 801- 805.
  • oligonucleotides are syn- thesized, e . g. , in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.
  • the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques.
  • the DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al . , (1988), Science 239, 1988, pp. 487-491.
  • mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.
  • a single-stranded gap of DNA, the glucoamylase-encoding sequence is created in a vector carrying the glucoamylase gene.
  • the synthetic nucleotide, bearing the desired mutation is annealed to a homologous portion of the single-stranded DNA. The remaining 18
  • PCR-generated fragment a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.
  • the random mutagenesis may be advantageously localized to a part of the parent glucoamylase m question. This may, e . g. , be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme .
  • the localized, or region-specific, random mutagenesis is conveniently performed by use of PCR generated mutagenesis techniques as described above or any other suitable technique known in the art.
  • the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e . g. , by insertion into a suitable vector, and said part may be subsequently subjected to mutagenesis by use of any of the mutagenesis methods discussed above.
  • a DNA sequence encoding the variant produced by methods described above, or by any alterna- tive methods known m the art can be expressed, enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ⁇ bosome bmdmg site, translation initiation signal, and, optionally, a repressor gene or various activator genes.
  • the recombmant expression vector carrying the DNA sequence encoding a glucoamylase variant of the invention may be any vector, which may conveniently be subjected to recombmant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome (s) into which it has been integrated. Examples of suitable expression vectors include pMT838.
  • the DNA sequence should be operably connected to a suitable promoter sequence .
  • the promoter may be any DNA sequence, which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
  • suitable promoters for directing the transcription of the DNA sequence encoding a glucoamylase variant of the invention, especially in a bacterial host are the promoter of the lac operon of E.
  • the Strep tomyces coelicolor agarase gene dagA promoters the promoters of the Bacillus licheni - formis alpha-amylase gene ⁇ amyL) , the promoters of the JBacillus stearothermophilus maltogenic amylase gene (amyM) , the promoters of the Bacillus amyloliquefaciens -amylase (amyQ) , the promoters of the Bacillus subtilis xylA and xylB genes etc.
  • useful promoters are those derived from the gene encoding A .
  • TPI riose phosphate isomerase
  • S. cerevisiae Alber et al . (1982), J. Mol . Appl . Genet 1, p. 419- 434
  • Rhizomucor miehei aspartic proteinase A . niger neutral alpha-amylase, A . niger acid stable alpha-amylase, A . niger glucoamylase, Rhizomucor miehei lipase, A . oryzae alkaline protease, A . oryzae triose phosphate isomerase or A . nidulans acetamidase .
  • the expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the alpha-amylase variant of the invention. Termina- tion and polyadenylation sequences may suitably be derived from the same sources as the promoter.
  • the vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUBHO, pE194, pAMBl and pIJ702.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the dal genes from B . subtilis or B . lichenifor- mis, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance.
  • a selectable marker e.g. a gene the product of which complements a defect in the host cell, such as the dal genes from B . subtilis or B . lichenifor- mis, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance.
  • the vector may comprise Aspergillus selection markers such as amdS, argB, niaD and sC, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e . g. , as described in WO 91/17243.
  • the cell of the invention is advantageously used as a host cell in the recombmant production of a glucoamylase variant of the invention.
  • the cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e . g. by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.
  • the cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g., a bacterial or a fungal (including yeast) cell.
  • a microbial cell e.g., a bacterial or a fungal (including yeast) cell.
  • suitable bacteria are Gram positive bacteria such as Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalophilus , Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus circulans, Bacillus lautus, Bacillus megaterium, Bacillus thuringiensis, or Streptomyces lividans or Streptomyces murinus, or gramnegative bacteria such as E. coli .
  • the trans- formation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known per se .
  • the yeast organism may favorably be selected from a species of Saccharomyces or Schizosaccharomyces, e. g. , Saccharomyces cerevisiae.
  • the host cell may also be a filamentous fungus, e.g., a strain belonging to a species of Aspergillus, most preferably Aspergillus oryzae or Aspergillus niger, or a strain of Fusarium, such as a strain of Fusarium oxysporium, Fusarium graminearum (in the perfect state named Gribberella zeae, previously Sphaeria zeae, synonym wi th Gibberella roseum and Gibberella roseum f. sp.
  • Fusarium sulphureum in the prefect state named Gibberella puricaris, synonym with Fusarium trichothecioides , Fusarium bactridioide ⁇ , Fusarium sambucium, Fusarium roseum, and Fusarium roseum var. graminearum) , Fusarium cerealis (synonym with Fusarium crokkwellnse) , or Fusarium venena turn.
  • the host cell is a protease deficient or protease minus strain.
  • This may for instance be the protease deficient strain Aspergillus oryzae JaL 125 having the alkaline protease gene named "alp" deleted.
  • This strain is described in WO 97/35956 (Novo Nordisk) , or EP patent no. 429,490.
  • Filamentous fungi cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se .
  • Aspergillus as a host microorganism is described in EP 238,023 (Novo Nordisk A/S) , the contents of which are hereby incorporated by reference.
  • the present invention relates to a method of producing a glucoamylase variant of the invention, which method comprises cultivating a host cell under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.
  • the medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the glucoamylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes ( e. g. as described in catalogues of the American Type Culture Collection) .
  • the glucoamylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.
  • the present invention provides a method of using glucoamylase variants of the invention for producing glucose and the like from starch.
  • the method includes the steps of partially hydrolyzing precursor starch in the presence of alpha-amylase and then further hydrolyzing the release of D- glucose from the non-reducing ends of the starch or related oligo- and polysaccharide molecules in the presence of glucoamylase by cleaving alpha- (1 ⁇ 4) and alpha- (1 ⁇ 6) glucosidic bonds .
  • the partial hydrolysis of the precursor starch utilizing ⁇ -amylase provides an initial breakdown of the starch molecules by hydrolyzing internal alpha- (1 ⁇ 4) -linkages .
  • the initial hydrolysis using alpha-amylase is run at a temperature of approximately 105°C.
  • a very high starch concentration is processed, usually 30% to 40% solids.
  • the initial hydrolysis is usually carried out for five minutes at this elevated temperature.
  • the partially hydrolyzed starch can then be transferred to a second tank and incubated for approximately one hour at a temperature of 85° to 90°C to derive a dextrose equivalent (D.E.) of 10 to 15.
  • D.E. dextrose equivalent
  • the step of further hydrolyzing the release of D-glucose from the non-reducing ends of the starch or related oligo- and polysaccharides molecules in the presence of glucoamylase is normally carried out in a separate tank at a reduced temperature between 30° and 60°C.
  • the temperature of the substrate liquid is dropped to between 55°C and 60°C.
  • the pH of the solution is dropped from 6 to 6.5 to a range between 3 and 5.5.
  • the pH of the solution is 4 to 4.5.
  • the glucoamylase is added to the solution and the reaction is carried out for 24-72 hours, preferably 36-48 hours.
  • thermostable glucoamylase variant of the invention saccharification processes may be carried out at a higher temperature than traditional batch saccharification processes.
  • saccharification may be carried out at temperatures in the range from above 60-80°C, preferably 63-75°C. This applied both for traditional batch processes (described above) and for continuous saccharification processes.
  • thermostable variants of the invention provides the possibility of carrying out large scale continuous saccharification processes at a fair price within and period of time acceptable for industrial saccharification processes. According to the invention the saccharification time may even be shortened.
  • the activity of the glucoamylase variant ⁇ e. g. , AMG variant) of the invention is generally substantially higher at temperatures between 60°C-80°C than at the traditionally used temperature between 30-60°C. Therefore, by increasing the temperature at which the glucoamylase operates the saccharification process may be carried out within a shorter period of time.
  • the T 1/2 (half- time, as defined in the "Materials and Methods" section) is improved.
  • the thermal stability of the glucoamylase variants of the invention is improved a minor amount of glucoamylase need to be added to replace the glucoamylase being inactivated during the saccharification process. More glucoamylase is maintained active during saccharification process according to the present invention.
  • the risk of microbial contamination is also reduced when carrying the saccharification process at temperature above 63°C.
  • glucoamylase variants of the invention include the processes described in JP 3-224493; JP 1-191693 ;JP 62-272987; and EP 452,238.
  • the glucoamylase variant (s) of the invention may be used in the present inventive process in combination with an enzyme that hydrolyzes only alpha- (1 ⁇ 6) -glucosidic bonds in molecules with at least four glucosyl residues.
  • the glucoamylase variant of the invention can be used in combination with pullulanase or isoamylase.
  • the use of isoamylase and pullulanase for debranching, the molecular properties of the enzymes, and the potential use of the enzymes with glucoamylase is set forth in G.M.A. van Beynum et al . ,
  • the invention relates to the use of a glucoamylase variant of the invention in a starch conversion process.
  • glucoamylase variant of the invention may be used in a continuous starch conversion process including a continuous saccharification step.
  • the glucoamylase variants of the invention may also be used in immobilised form. This is suitable and often used for producing maltodextrins or glucose syrups or speciality syrups, such as maltose syrups, and further for the raffinate stream of oligosaccharides in connection with the production of fructose syrups .
  • the AMG variant of the invention may also be used for producing ethanol , e.g., for fuel or drinking.
  • a contemplated method is described in US patent no. 5,231,017.
  • AMG Gl Aspergillus niger glucoamylase Gl disclosed in Boel et al., (1984), EMBO J. 3 (5), 1097-1102, (SEQ ID NO: 13), available from Novo Nordisk.
  • AMG G2 Truncated Aspergillus niger glucoamylase Gl shown in SEQ ID NO: 2, available from Novo Nordisk)
  • a . oryzae JaL 125 Aspergillus oryzae IFO 4177 available from Institute for Fermention, Osaka; 17-25 Juso Hammachi 2- Chome Yodogawa-ku, Osaka, Japan, having the alkaline protease gene named "alp” (described by Murakami K et al . , (1991), Agric. Biol. Chem. 55, p. 2807-2811) deleted by a one step gene replacement method (described by G. May in "Applied Molecular Genetics of Filamentous Fungi” (1992), p. 1-25. Eds. J. R. Kinghorn and G. Turner; Blackie Academic and Professional) , using the A . oryzae pyrG gene as marker.
  • Strain JaL 125 is further disclosed in WO 97/35956 (Novo Nordisk) .
  • Saccharomyces cerevisiae YNG318 MAT ⁇ leu2- ⁇ 2 ura3-52 his4-539 pep4- ⁇ l [cir+]
  • Plasmids pCAMG91: see Figure 1. Plasmid comprising the Aspergillus niger Gl glucoamylase (AMG Gl) . The construction of pCAMG91 is described in Boel et al . (1984), EMBO J. 3 (7) p.1581-1585. pMT838: Plasmid encoding the truncated Aspergillus niger 5 glucoamylase G2 (SEQ ID NO : 2) . pJSO026 (S. cerevisiae expression plasmid) (J.S.Okkels,
  • the DNA fragments and the opened vectors are mixed and transformed into the yeast Saccharomyces cerevisiae YNG318 by standard methods .
  • microL substrate 1% maltose, 50 mM Sodium acetat, pH 4.3
  • selected temperature such as
  • AGU Activity Determination Of AGU Activity and As AGU/mg
  • AGU/mg One Novo Amyloglucosidase Unit (AGU) is defined as the amount of enzyme, which hydrolyzes 1 micromole maltose per minute at 37°C and pH 4.3.
  • a detailed description of the analytical method (AEL-SM-0131) is available on request from Novo Nordisk .
  • the activity is determined as AGU/ml by a method modified after (AEL-SM-0131) using the Glucose GOD-Perid kit from Boehringer Mannheim, 124036. Standard: AMG-standard, batch 7- 1195, 195 AGU/ml.
  • microL substrate 1% maltose in 50 mM Sodium acetate, pH 4.3
  • 25 microL enzyme diluted in sodium acetate is added.
  • the reaction is stopped after 10 minutes by adding 100 microL 0.25 M NaOH.
  • 20 microL is transferred to a 96 well microtitre plate and 200 microL GOD-Perid solution is added. After 30 minutes at room temperature, the absorbance is measured at 650 nm and the activity calculated in AGU/ml from the AMG-standard.
  • AGU/mg The specific activity in AGU/mg is then calculated from the activity (AGU/ml) divided with the protein concentration (mg/ml) .
  • the suspension is cooled on ice and 1 ml of buffer containing
  • the suspension is filtered through miracloth, the filtrate transferred to a sterile tube and overlayed with 5 ml of 0.6 M sorbitol, 100 mM Tris-HCl, pH 7.0. Centrifugation is performed for 15 mm. at 1000 g and the protoplasts are collected from the top of the MgS ⁇ 4 cushion. 2 volumes of STC (1.2 M sorbitol, 10 mM Tris-HCl, pH 7.5 , 10 mM CaCl 2 ) are added to the protoplast suspension and the mixture is cent ⁇ fugated for 5 mm. at 1000 g. The protoplast pellet is resuspended in 3 ml of STC and repelleted. This is repeated. Finally, the protoplasts are resuspended m 0.2-1 ml of STC.
  • p3SR2 an A . nidulans amdS gene carrying plasmid described in Hynes et al . , Mol . and Cel . Biol., Vol. 3, No. 8, 1430-1439,
  • Fed batch fermentation is performed m a medium comprising maltodextrm as a carbon source, urea as a nitrogen source and yeast extract.
  • the fed batch fermentation is performed by inoculating a shake flask culture of A . oryzae host cells m question into a medium comprising 3.5% of the carbon source and 0.5% of the nitrogen source. After 24 hours of cultivation at pH 5.0 and 34°C the continuous supply of additional carbon and nitrogen sources are initiated. The carbon source is kept as the limiting factor and it is secured that oxygen is present in excess.
  • the fed batch cultivation is continued for 4 days, after which the enzymes can be recovered by centrifugation, ultrafiltration, clear filtration and germ filtration.
  • the culture broth is filtrated and added ammoniumsulphate (AMS) to a concentration of 1.7 M AMS and pH is adjusted to pH 5.
  • AMS ammoniumsulphate
  • Precipitated material is removed by centrifugation and the solution containing glucoamylase activity is applied on a Toyo Pearl Butyl column previously equilibrated in 1.7 M AMS, 20 mM sodium acetate, pH 5. Unbound material is washed out with the equilibration buffer.
  • Bound proteins are eluted with 10 mM sodium acetate, pH 4.5 using a linear gradient from 1.7 - 0 M AMS over 10 column volumes.
  • Glucoamylase containing fractions are collected and dialysed against 20 mM sodium acetate, pH 4.5.
  • the thermal stability of variants is determined as T 1/2 using the following method: 950 microliter 50 mM sodium acetate buffer (pH 4.3) (NaOAc) is incubated for 5 minutes at
  • the T 1/2 is measured by incubating the enzyme (ca 0.2 AGU/ml) in question in 30% glucose, 50 mM Sodium acetate at pH
  • Samples are withdrawn at set time intervals and chilled on ice and residual enzyme activity measured by the pNPG method (as described below) .
  • the % residual glucoamylase activity is determined at different times. T 1/2 is the period of time until which the % relative activity is decreased to 50%.
  • Residual Enzyme Activity pNPG method
  • pNPG reagent 0.2 g pNPG (p-nitrophenylglucopyranoside) is dissolved in 0.1
  • 25 microL samples are added 50 microL substrate and incubated 2 hr at 50°C.
  • the reaction is stopped by adding 150 micoL ml borate solution.
  • the optical density is measured at 405 nm, and the residual activity calculated.
  • the pAMGY vector was constructed as follows: The lipase gene in pJSO026 was replaced by the AMG gene, which was PCR amplified with the forward primer; FG2 : 5' -CAT CCC CAG GAT CCT TAC TCA GCA ATG-3' (SEQ ID NO: 10) and the reverse primer: RG2 : 5'-CTC AAA CGA CTC ACC AGC CTC TAG AGT-3' (SEQ ID NO: 11) using the template plasmid pLAC103 containing the AMG gene.
  • the pJSO026 plasmid was digested with Xbal and Smal at 37°C for 2 hours and the PCR amplicon was blunt ended using the Klenow fragment and then digested with Xbal .
  • the vector fragment and the PCR amplicon were ligated and transformed into E. coli by electrotransformation.
  • the resulting vector is designated pAMGY.
  • the A . niger AMGII cDNA clone (Boel et al . , (1984), supra) is used as source for the construction of pLaC103 aimed at S. cerevisiae expression of the Gil form of AMG. The construction takes place in several steps, out lined below.
  • pT7-212 (EP37856/ US patent no. 5162498) is cleaved with Xbal, blunt-ended with Klenow DNA polymerase and dNTP.
  • the resulting vector fragment is purified from an agarose gel-electrophoresis and ligated with the 2.05 kb EcoRI-EcoRV fragment of pBoel53, thereby recreating the Xbal site in the EcoRV end of the AMG encoding fragment in the resulting plasmid pG2x.
  • the 930 bp EcoRI-Pstl fragment of p53 was isolated and subjected to Alul cleavage, the resulting 771 bp Alu-Pstl fragment was ligated into pBR322 with blunt-ended EcoRI site (see above) and cleaved with Pstl In the resulting plasmid pBR-AMG' , the EcoRI site was recreated just 34 bp from the initiation codon of the AMG cds.
  • the resulting plasmid pT7GII was submitted to a BamHI cleavage in presence of alkaline phosphatase followed by partial Sphl cleavage after inactivation of the phosphatase.
  • thermostable filter assay The libraries are screened in the thermostable filter assay described below.
  • Yeast libraries are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany) - and nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell,
  • the PVDF filters with bound variants are transferred to a container with 0.1 M NaAc, pH 4.5 and incubated at 47°C or alternatively 67-69°C in case of Protran filters for 15 minutes.
  • the sandwich of cellulose acetate and nitrocellulose filters on SC ura-agar plates are stored at room temperature until use. After incubation, the residual activities are detected on plates containing 5% maltose, 1% agarose, 50 mM NaAc, pH 4.5.
  • the assay plates with PVDF filters are marked the same way as the filter sandwiches and incubated for 2 hrs. at 50°C. After removal of the PVDF filters, the assay plates are stained with Glucose GOD perid (Boehringer Mannheim GmbH, Germany) . Variants with residual activity are detected on assay plates as dark green spots on white background. The improved variants are located on the storage plates. Improved variants are rescreened twice under the same conditions as the first screen.
  • the random mutagenesis may be carried out by the following steps :
  • Suitable dope algorithms for use in step 6 are well known m the art.
  • One such algorithm is described by Tomandl , D. et al . , 1997, Journal of Computer-Aided Molecular Design 11:29-38.
  • DOPE Jikkensen, LJ, Andersen, KV, Svendsen, A, and Kretzschmar, T (1998) Nucleic Acids Research 26:697- 702) .
  • the gene encoding the AMG G2 enzyme in question is located on pMT838 prepared by deleting the DNA between G2 nt . 1362 and is G2 nt . 1530 in plasmid pCAMG91 (see Figure 1) comprising the
  • the pMT838 vector comprising the AMG gene in question was then 25 used as a template for DNA polymerase and oligo 7258 (SEQ ID NO:
  • Primer no. 21401 (SEQ ID NO : 4) was used as the selection primer.
  • the desired mutation (e.g., the introduction of a cystein residue) is introduced into the AMG gene in question by 5 addition of an appropriate oligos comprising the desired mutation.
  • the primer 107581 was used to introduce T12P
  • the mutations are verified by sequencing the whole gene.
  • the plasmid was transformed into A . oryzae using the method described above in the "Materials and Methods” section.
  • the variant was fermented and purified as described above in the "Materials & Methods” section.
  • Region L19-G35 Region: A353-V374
  • the DOPE software (see Materials and Methods) was used to determine spiked codons for each suggested change in the above regions minimizing the amount of stop codons (see table 1) .
  • the exact distribution of nucleotides was calculated in the three positions of the codon to give the suggested population of amino acid changes.
  • the doped regions were doped specifically in the indicated positions to have a high chance of getting the desired residues, but still allow other possibilities .
  • the first column is the amino acid to be mutated, the second column is the percentage of wild type and the third column defined the new amino acid(s) .
  • the resulting doped oligonucleotide strand is shown in is table 2 as sense strand: with the primer sequence, the wild type nucleotide sequence, the parent amino acid sequence and the distribution of nucleotides for each doped position.
  • A. a. seq. L N N I G A D G
  • a primer 12T A3T AAC ATC G4G 5CG 67C G4T 8CT wt . seq . : CTG AAT AAC ATC GGG GCG GAC GGT GCT
  • A. a. (cont.) W V S G A D S G primer: 91010 GTG 1112C G4C G13G 141516 1718T GGC
  • Reverse primer (SEQ ID NO: 7) :
  • RAMGl 5' -GAT GGC AGT ACG AGC CAC GGT CGC TTC G-3'
  • the resulting doped oligonucleotide strand is shown in table 4 as sense strand: with the primer sequence, wild type nucleotide sequence, the parent amino acid sequence and the distribution of nucleotides for each doped position.
  • Primer RAMGVI (SEQ ID NO: 9) 5'-ctt gaa gaa gtc cag cga cac-3'
  • GCA ATG-3' (SEQ ID NO: 10) and C-terminal (RG2 : 5'- CTC AAA CGA CTC ACC AGC CTC TAG AGT (SEQ ID NO: 11) are used to generate PCR-library-fragments by the overlap extension method (Horton et al., Gene, 77 (1989), pp. 61-68) with an overlap of 21 base pairs.
  • Plasmid pAMGY is template for the Polymerase Chain Reaction. The PCR fragments are cloned by homologous recombination in the E. coli/yeast shuttle vector pAMGY (see Materials and Methods) .
  • thermostability filter assays using a Protran filter and incubating at 67-69°C as described in the "Material & Methods" section above EXAMPLE 2
  • AMG G2 variants were constructed using the approach described in Example 1.
  • thermostability was determined as T using Method
  • AMG G2 variants were constructed as described above in Example 1.
  • the specific activity as k cat or AGU/mg was measured at pH 4.5, 37°C, using maltose as substrates as described in the "Materials & Methods" section above.
  • thermostability was determined as T% using method
  • thermostability (see Example 4) is tested at 70°C as described below.
  • Reference enzyme is the wild-type A . niger AMG G2.
  • the substrate for saccharification is made by dissolving maltodextrin (prepared from common corn) in boiling Milli-Q water and adjusting the dry substance to approximately 30%
  • Enzymes are added and pH re-adjusted if necessary. The experiment is run in duplicate. Samples are taken periodically and analysed at HPLC for determination of the carbohydrate composition.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une variante d'une amylase fongique antériologue, présentant des propriétés modifiées, en particulier une stabilité thermique améliorée et/ou une activité spécifique augmentée.
EP00943688A 1999-07-09 2000-07-07 Variante de glucoamylase Ceased EP1200566A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08159171A EP2009098A1 (fr) 1999-07-09 2000-07-07 Variante de glucoamylase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK99999 1999-07-09
DKPA199900999 1999-07-09
PCT/DK2000/000373 WO2001004273A2 (fr) 1999-07-09 2000-07-07 Variante de glucoamylase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08159171A Division EP2009098A1 (fr) 1999-07-09 2000-07-07 Variante de glucoamylase

Publications (1)

Publication Number Publication Date
EP1200566A2 true EP1200566A2 (fr) 2002-05-02

Family

ID=8099879

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00943688A Ceased EP1200566A2 (fr) 1999-07-09 2000-07-07 Variante de glucoamylase
EP08159171A Withdrawn EP2009098A1 (fr) 1999-07-09 2000-07-07 Variante de glucoamylase

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08159171A Withdrawn EP2009098A1 (fr) 1999-07-09 2000-07-07 Variante de glucoamylase

Country Status (8)

Country Link
US (3) US7354753B2 (fr)
EP (2) EP1200566A2 (fr)
JP (1) JP2003504046A (fr)
CN (2) CN101550410A (fr)
AR (2) AR029759A1 (fr)
AU (1) AU5805700A (fr)
CA (1) CA2374009A1 (fr)
WO (1) WO2001004273A2 (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352851B1 (en) * 1998-07-15 2002-03-05 Novozymes A/S Glucoamylase variants
AU5805700A (en) * 1999-07-09 2001-01-30 Novozymes A/S Glucoamylase variant
EP1370648A2 (fr) 2000-08-01 2003-12-17 Novozymes A/S Mutants d'alpha-amylase a proprietes modifiees
WO2002092797A2 (fr) 2001-05-15 2002-11-21 Novozymes A/S Variant d'alpha-amylases ayant des proprietes modifiees
US7371546B2 (en) 2001-10-01 2008-05-13 Novozymes A/S Glucoamylase variants
JP4897186B2 (ja) * 2002-03-27 2012-03-14 花王株式会社 変異アルカリセルラーゼ
ES2278210T3 (es) * 2002-12-17 2007-08-01 Novozymes A/S Alfa-amilasas termoestables.
WO2004106533A1 (fr) 2003-05-30 2004-12-09 Novozymes A/S Procedes de fabrication de produits d'alcool
CN102796717A (zh) 2003-07-07 2012-11-28 金克克国际有限公司 外切特异性的淀粉酶多肽、编码那些多肽的核酸及其应用
US8143048B2 (en) 2003-07-07 2012-03-27 Danisco A/S Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof
ES2340390T3 (es) 2003-10-28 2010-06-02 Novozymes North America, Inc. Enzimas hibridas.
DE102004026152A1 (de) * 2004-05-28 2005-12-15 Basf Ag Fermentative Herstellung von Feinchemikalien
ES2648900T3 (es) * 2004-07-07 2018-01-08 Dupont Nutrition Biosciences Aps Variantes de exoamilasa
EP2365068B1 (fr) 2004-12-22 2017-03-01 Novozymes A/S Enzymes pour le traitement de l'amidon
US8030050B2 (en) 2005-07-07 2011-10-04 Danisco A/S Modified amylases from Pseudomonas species
WO2007035730A2 (fr) 2005-09-20 2007-03-29 Novozymes North America, Inc. Procédé de production d'un produit de fermentation
US20080318284A1 (en) 2005-12-22 2008-12-25 Novozymes North America, Inc. Processes for Producing a Fermentation Product
CN100443589C (zh) * 2005-12-30 2008-12-17 湖南鸿鹰祥生物工程股份有限公司 高转化率高纯度糖化酶浓缩液的生产方法
WO2007109750A2 (fr) 2006-03-22 2007-09-27 Novozymes North America, Inc. processus de fermentation
WO2007148224A2 (fr) 2006-06-19 2007-12-27 Danisco A/S Polypeptide
MX2009003472A (es) 2006-10-10 2009-06-02 Danisco Us Inc Genencor Div Variantes de glucoamilasa con propiedades alteradas.
CN101668863B (zh) 2007-04-24 2014-12-03 诺维信北美公司 使经预处理的含木质纤维素的材料解毒
ES2425596T3 (es) 2007-09-03 2013-10-16 Novozymes A/S Detoxificación y reciclaje de soluciones de lavado utilizadas en el pretratamiento de materiales con contenido de lignocelulosa
US8592194B2 (en) 2007-10-09 2013-11-26 Danisco Us Inc. Glucoamylase variants with altered properties
BRPI0817853B1 (pt) * 2007-10-09 2022-05-10 Danisco Us Inc Variantes de glucoamilase com propriedades alteradas, método de produção das mesmas, composição de enzima e microorganismo transgênico
EP2222842B1 (fr) * 2007-11-20 2014-10-15 Danisco US Inc. Variants de glucoamylase ayant des propriétés modifiées
WO2009129086A2 (fr) * 2008-04-18 2009-10-22 New England Biolabs, Inc. Endoglycosidases clivant des glycanes à liaison o
BRPI0913402B1 (pt) 2008-06-06 2019-07-02 Danisco Us Inc. Alfa amilases (amys) variantes de geobacillus stearothermophilus com propriedades melhoradas
EP2364363A2 (fr) 2008-06-23 2011-09-14 Novozymes A/S Procédés de production de produits de fermentation
ES2480265T3 (es) 2008-09-30 2014-07-25 Novozymes North America, Inc. Mejora de la hidrólisis enzimática de material que contiene lignocelulosa pretratado con granos secos de destilería
ES2526867T3 (es) 2008-11-20 2015-01-16 Novozymes Inc. Polipéptido que tiene actividad potenciadora amilolítica y polinucleótidos que codifican el mismo
WO2010078391A2 (fr) 2008-12-30 2010-07-08 Novozymes North America, Inc. Amélioration d'une hydrolyse enzymatique d'une matière prétraitée contenant de la lignocellulose avec de la boue d'aéroflottation dissoute
WO2010078392A2 (fr) 2008-12-31 2010-07-08 Novozymes North America, Inc. Procédés de production de produits de fermentation
CN102471784A (zh) 2009-07-07 2012-05-23 诺维信公司 用酶处理底物的方法
MX2012000322A (es) 2009-07-17 2012-02-08 Novozymes As Metodo de analisis del decaimiento de la celulosa en la hidrolisis del material celulosico.
EP2467474A1 (fr) * 2009-08-19 2012-06-27 Danisco A/S Variants de glucoamylase
CN102665425A (zh) 2009-09-30 2012-09-12 诺维信公司 馒头制备方法和馒头改进组合物
WO2011087836A2 (fr) 2009-12-22 2011-07-21 Novozymes A/S Variants de pullulanase et utilisations de ceux-ci
WO2011092136A1 (fr) 2010-01-29 2011-08-04 Novozymes A/S Procédé de production de biogaz avec prétraitement enzymatique
WO2011100161A1 (fr) 2010-02-09 2011-08-18 Novozymes North America, Inc. Addition d'alpha-glucosidase et de cobalt pour préparer des produits de fermentation à partir d'amidon
EP3070171B1 (fr) 2010-03-30 2018-06-13 Novozymes A/S Procede pour augmenter les produits secondaires de procedes de fermentation
MX338068B (es) 2010-04-14 2016-04-01 Novozymes As Polipeptidos que tienen actividad de glucoamilasa y polinucleotidos que codifican los mismos.
DK2579727T3 (en) 2010-06-11 2018-11-26 Novozymes As Enzymatic milk correction
US9308064B2 (en) 2010-07-26 2016-04-12 Johnson & Johnson Consumer Inc. Devices and methods for collecting and analyzing fluid samples from the oral cavity
CN103140586A (zh) 2010-08-02 2013-06-05 诺维信北美公司 产生发酵产物的方法
BR112013012357A2 (pt) 2010-11-19 2016-10-11 Novozymes North America Inc processos de produzir um produto de fermentação, de produzir um açúcar, de produzir uma dextrina e de produzir sacarose, e, composição
ES2673940T3 (es) 2010-12-22 2018-06-26 Novozymes North America, Inc. Proceso para producir productos de fermentación a partir de materiales que contienen almidón
WO2012093041A1 (fr) 2011-01-04 2012-07-12 Novozymes A/S Procédé de production d'un gaz biologique à partir d'un matériau contenant de la pectine et de la lignocellulose
EP2673368B1 (fr) 2011-02-07 2014-12-24 Novozymes North America, Inc. Procédé de liquéfaction d'amidon en présence de pyridoxamine
US20140106427A1 (en) 2011-06-28 2014-04-17 Novozymes A/S Biogas From Enzyme-Treated Bagasse
JP6204352B2 (ja) 2011-06-30 2017-09-27 ノボザイムス アクティーゼルスカブ α−アミラーゼ変異体
EA201490216A1 (ru) 2011-07-06 2014-07-30 Новозимс А/С Варианты альфа-амилазы и кодирующие их полинуклеотиды
US20140147895A1 (en) 2011-07-22 2014-05-29 Novozymes A/S Processes for Pretreating Cellulosic Material and Improving Hydrolysis Thereof
EP2742350B1 (fr) 2011-08-08 2019-10-30 The Coca-Cola Company Lignées cellulaires comprenant des récepteurs endogènes du goût, et leurs utilisations
IN2014CN03467A (fr) 2011-10-11 2015-10-16 Novozymes North America Inc
IN2014CN04905A (fr) 2011-12-02 2015-09-18 Novozymes As
WO2013083801A2 (fr) 2011-12-09 2013-06-13 Novozymes A/S Biogaz obtenu à partir de substrats comprenant du fumier de ferme et des enzymes
EP2794899A1 (fr) 2011-12-21 2014-10-29 Novozymes, Inc. Procédés de détermination de dégradation d'une matière de biomasse
ES2935920T3 (es) 2012-03-30 2023-03-13 Novozymes North America Inc Procesos de elaboración de productos de fermentación
US9856498B2 (en) 2012-03-30 2018-01-02 Novozymes A/S Processes of producing fermentation products
CN104540394A (zh) 2012-08-17 2015-04-22 诺维信公司 热稳定天冬酰胺酶变体以及对其进行编码的多核苷酸
EP2893009A4 (fr) 2012-09-07 2016-03-02 Novozymes As Variants de glucoamylase et polynucléotides codant pour ceux-ci et utilisations de ceux-ci
CN104870631A (zh) * 2012-12-11 2015-08-26 丹尼斯科美国公司 表达来自烟曲霉的葡糖淀粉酶的里氏木霉宿主细胞和其使用方法
DK3022300T3 (en) 2013-07-17 2018-10-22 Novozymes As : Pullulan chimeras and polynucleotides encoding them
EP3063282B1 (fr) 2013-09-11 2020-03-25 Novozymes A/S Procédés de production de produits de fermentation
DK3097192T3 (en) 2014-01-22 2018-11-19 Novozymes As PULLULANASE VARIATIONS AND POLYNUCLEOTIDES CODING THEM
RU2019134734A (ru) 2014-02-07 2019-11-18 Новозимс А/С Композиции для получения глюкозных сиропов
WO2015143144A1 (fr) 2014-03-19 2015-09-24 Novozymes A/S Procédé destiné à augmenter l'activité d'un polypeptide x143
EP3129478B1 (fr) 2014-04-10 2019-03-27 Novozymes A/S Variants d'alpha-amylase et polynucléotides codant pour ces derniers
ES2743515T3 (es) 2014-10-23 2020-02-19 Novozymes As Variantes de glucoamilasa y polinucleótidos que codifican las mismas
US20170321237A1 (en) 2014-12-01 2017-11-09 Novozymes A/S Improved Production of Glucose Syrups
CA2981342A1 (fr) 2015-06-18 2016-12-22 Novozymes A/S Polypeptides ayant une activite trehalase et leur utilisation dans un procede de production de produits de fermentation
WO2017112533A1 (fr) 2015-12-22 2017-06-29 Novozymes A/S Procédé d'extraction d'huile à partir de résidus de distillation fin
US10067091B2 (en) 2016-07-29 2018-09-04 Saudi Arabian Oil Company Integrated sediment and water analysis device and method
EP3526336A1 (fr) 2016-10-17 2019-08-21 Novozymes A/S Procédés de réduction de la mousse pendant la fermentation d'éthanol
US10889836B2 (en) 2016-11-23 2021-01-12 Novozymes A/S Yeast for ethanol production
MX2019011900A (es) * 2017-04-11 2019-12-05 Novozymes As Variantes de glucoamilasa y polinucleotidos que las codifican.
AU2018262815A1 (en) * 2017-05-05 2019-11-07 New Matterhorn, Llc Glucose isomerase
WO2018222990A1 (fr) 2017-06-02 2018-12-06 Novozymes A/S Levure améliorée pour la production d'éthanol
US11584783B2 (en) 2017-06-28 2023-02-21 Novozymes A/S Processes for producing a fermentation product
US11220679B2 (en) 2017-08-08 2022-01-11 Novozymes A/S Polypeptides having trehalase activity
CN111164214A (zh) 2017-09-15 2020-05-15 诺维信公司 用于改进动物饲料营养质量的酶共混物和方法
CA3075907A1 (fr) 2017-10-23 2019-05-02 Novozymes A/S Procedes pour la reduction d'acide lactique dans un systeme de fermentation de biocarburant
CA3089135A1 (fr) 2018-01-29 2019-08-01 Novozymes A/S Micro-organismes a utilisation amelioree d'azote pour la production d'ethanol
MX2020008309A (es) 2018-02-15 2020-10-14 Novozymes As Levadura mejorada para produccion de etanol.
EP3810785A2 (fr) 2018-05-31 2021-04-28 Novozymes A/S Procédés d'amélioration de la croissance et de la productivité de levures
US20210269833A1 (en) 2018-07-11 2021-09-02 Novozymes A/S Processes for producing fermentation products
CA3107110A1 (fr) 2018-07-25 2020-01-30 Novozymes A/S Levure exprimant une enzyme pour la production d'ethanol
WO2020076697A1 (fr) 2018-10-08 2020-04-16 Novozymes A/S Levure exprimant une enzyme pour la production d'éthanol
US11622751B2 (en) 2018-12-19 2023-04-11 Johnson & Johnson Consumer Inc. Devices and methods for collecting saliva samples from the oral cavity
WO2020160126A1 (fr) 2019-01-31 2020-08-06 Novozymes A/S Polypeptides ayant une activité xylanase et leur utilisation pour améliorer la qualité nutritionnelle d'aliments pour animaux
EP3947701A1 (fr) 2019-04-02 2022-02-09 Novozymes A/S Procédé de production d'un produit de fermentation
WO2021007379A1 (fr) 2019-07-09 2021-01-14 Dupont Nutrition Biosciences Aps Compositions à enzymes particulaires enrobées de matière grasse
EP4004029A1 (fr) 2019-07-26 2022-06-01 Novozymes A/S Micro-organismes à transport d'azote amélioré pour la production d'éthanol
BR112022002203A2 (pt) 2019-08-05 2022-09-06 Novozymes As Misturas de enzimas e processos para produção de um ingrediente alimentar com alto teor de proteína a partir de um subproduto de vinhaça completa
MX2021015818A (es) 2019-08-06 2022-02-03 Novozymes As Proteinas de fusion para mejorar la expresion de enzimas.
WO2021046073A1 (fr) 2019-09-05 2021-03-11 Dupont Nutrition Biosciences Aps Composition d'aliment pour animaux
EP4031661A1 (fr) 2019-09-16 2022-07-27 Novozymes A/S Polypeptides dotés d'une activité bêta-glucanase et polynucléotides codant pour ces polypeptides
BR112022011271A2 (pt) 2019-12-10 2022-09-06 Novozymes As Célula hospedeira recombinante, composição, métodos para produzir um derivado de uma célula e um produto de fermentação, e, uso de uma célula hospedeira recombinante
AR120775A1 (es) 2019-12-16 2022-03-16 Novozymes As Procesos para obtener productos de fermentación
EP4103709A2 (fr) 2020-02-10 2022-12-21 Novozymes A/S Polypeptides ayant une activité alpha-amylase et polynucléotides codant pour ces derniers
MX2023004938A (es) 2020-11-02 2023-05-17 Novozymes As Variantes de glucoamilasa y polinucleotidos que codifican las mismas.
BR112023025624A2 (pt) 2021-06-07 2024-02-27 Novozymes As Célula de levedura recombinante, célula hospedeira recombinante, composição, cocultura, métodos de produção de um derivado de uma célula hospedeira recombinante e de produção de um produto de fermentação, e, uso de uma célula hospedeira recombinante
CA3232987A1 (fr) 2021-09-27 2023-03-30 Marion BERNARDEAU Compositions d'additifs alimentaires et leurs procedes d'utilisation
WO2023064905A1 (fr) * 2021-10-15 2023-04-20 Danisco Us Inc. Variantes de glucoamylase et leurs procédés d'utilisation
WO2023225510A1 (fr) 2022-05-17 2023-11-23 Dupont Nutrition Biosciences Aps Additif alimentaire comprenant des combinaisons d'enzymes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272326A (en) 1980-01-24 1981-06-09 Allied Chemical Corporation Enhanced distillation of cyclohexanol from phenol with additional cyclohexanone feed
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
JPS62272987A (ja) 1986-05-22 1987-11-27 Hitachi Plant Eng & Constr Co Ltd ブドウ糖の製造方法
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01191693A (ja) 1988-01-25 1989-08-01 Tdk Corp デンプンの連続的糖化方法
CA1333777C (fr) 1988-07-01 1995-01-03 Randy M. Berka Champignons filamenteux deficients en proteinase aspartique
JP2733330B2 (ja) 1989-08-31 1998-03-30 日本食品化工株式会社 高純度澱粉糖の製造方法
CA2038485A1 (fr) 1990-03-23 1991-09-24 Donald K. Hadden Procede de nanofiltration pour la fabrication du dextrose
DE69107455T3 (de) 1990-05-09 2004-09-23 Novozymes A/S Eine ein endoglucanase enzym enthaltende zellulasezubereitung.
US5162210A (en) * 1990-06-29 1992-11-10 Iowa State University Research Foundation Process for enzymatic hydrolysis of starch to glucose
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US5665585A (en) * 1992-09-03 1997-09-09 Alko-Yhiot Oy Recombinant production of glucoamylase P in trichoderma
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE4422198C2 (de) 1994-06-24 1997-08-28 Audi Ag Verfahren zum Steuern der elektrischen Beheizung eines Katalysators
AU2152897A (en) 1996-03-27 1997-10-17 Novo Nordisk A/S Alkaline protease deficient filamentous fungi
CA2259958A1 (fr) * 1996-07-24 1998-01-29 Martin Allen Fabrication par genie genetique et a l'aide de proteines d'une glucoamylase permettant d'obtenir un ph optimal et d'accroitre la specificite d'un substrat ainsi que la stabilite thermique
US6255084B1 (en) * 1997-11-26 2001-07-03 Novozymes A/S Thermostable glucoamylase
DK1032654T3 (da) 1997-11-26 2009-05-11 Novozymes As Thermostabil glucoamylase
US6352851B1 (en) * 1998-07-15 2002-03-05 Novozymes A/S Glucoamylase variants
CA2352046A1 (fr) * 1998-12-07 2000-06-15 Novozymes A/S Gluco-amylases a extensions n-terminales
US6329186B1 (en) * 1998-12-07 2001-12-11 Novozymes A/S Glucoamylases with N-terminal extensions
AU5805700A (en) * 1999-07-09 2001-01-30 Novozymes A/S Glucoamylase variant
EP2236611A1 (fr) * 2000-04-28 2010-10-06 Novozymes A/S Variant d'enzyme lipolytique
ES2340390T3 (es) * 2003-10-28 2010-06-02 Novozymes North America, Inc. Enzimas hibridas.
US7464662B2 (en) * 2004-01-28 2008-12-16 Tokyo Electron Limited Compact, distributed inductive element for large scale inductively-coupled plasma sources

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0104273A2 *

Also Published As

Publication number Publication date
AR069653A2 (es) 2010-02-10
AU5805700A (en) 2001-01-30
JP2003504046A (ja) 2003-02-04
US20040002142A1 (en) 2004-01-01
US8722369B2 (en) 2014-05-13
US20120208243A1 (en) 2012-08-16
CN100510067C (zh) 2009-07-08
CA2374009A1 (fr) 2001-01-18
AR029759A1 (es) 2003-07-16
WO2001004273A3 (fr) 2001-09-07
EP2009098A1 (fr) 2008-12-31
US7927857B2 (en) 2011-04-19
WO2001004273A2 (fr) 2001-01-18
US7354753B2 (en) 2008-04-08
CN101550410A (zh) 2009-10-07
US20080213843A1 (en) 2008-09-04
CN1360630A (zh) 2002-07-24

Similar Documents

Publication Publication Date Title
US8722369B2 (en) Glucoamylase variants
US8426183B2 (en) Glucoamylase variants
EP1097196B2 (fr) Variants de glucoamylase
US8222006B2 (en) Glucoamylase variants
US6329186B1 (en) Glucoamylases with N-terminal extensions
WO2000034452A1 (fr) Gluco-amylases a extensions n-terminales
EP1914306A2 (fr) Variantes de la glucoamylase
CN101275125A (zh) 葡糖淀粉酶变体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20020307

17Q First examination report despatched

Effective date: 20030528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080725